{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:04:54Z","timestamp":1791295494704,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ijcard.2015.02.008","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T02:21:41Z","timestamp":1423534901000},"page":"96-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy"],"prefix":"10.1016","volume":"184","author":[{"given":"Giuseppe","family":"Vergaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Del Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Giannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Prontera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ripoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Barison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Giorgio","family":"Masci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Donato","family":"Aquaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cohen Solal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Padeletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Passino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2015.02.008_bb0005","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/CIRCULATIONAHA.104.500546","article-title":"Mechanisms and models in heart failure: the biomechanical model and beyond","volume":"111","author":"Mann","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.02.008_bb0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/CIRCIMAGING.113.000438","article-title":"Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study","volume":"6","author":"Masci","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2015.02.008_bb0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMcp0909392","article-title":"Clinical practice. Systolic heart failure","volume":"362","author":"McMurray","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.hrtlng.2007.12.002","article-title":"Diastolic heart failure","volume":"37","author":"Gary","year":"2008","journal-title":"Heart Lung"},{"key":"10.1016\/j.ijcard.2015.02.008_bb0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcard.2010.11.005","article-title":"Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy","volume":"157","author":"Masci","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0030","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2013.1363","article-title":"Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy","volume":"309","author":"Gulati","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2015.02.008_bb0035","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.02.008_bb0040","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1161\/CIRCHEARTFAILURE.112.000146","article-title":"Galectin-3 and cardiac function in survivors of acute myocardial infarction","volume":"6","author":"Weir","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann. Med."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study","volume":"99","author":"Lok","year":"2010","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00392-012-0500-y","article-title":"Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure","volume":"102","author":"Lok","year":"2013","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0065","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","article-title":"Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies","volume":"93","author":"Richardson","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.02.008_bb0070","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1515\/CCLM.2004.108","article-title":"Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure","volume":"42","author":"Emdin","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"Yu","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0080","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCHEARTFAILURE.113.000996","article-title":"The incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure","volume":"7","author":"Masci","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0085","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2010.11.013","article-title":"Assessment of myocardial fibrosis with cardiovascular magnetic resonance","volume":"57","author":"Mewton","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0090","doi-asserted-by":"crossref","first-page":"12A","DOI":"10.1016\/0002-9149(93)90239-9","article-title":"Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension","volume":"71","author":"Brilla","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0095","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/hy1101.099484","article-title":"Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship","volume":"38","author":"Zannad","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.02.008_bb0100","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/0002-9149(87)90618-7","article-title":"Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients","volume":"60","author":"Roberts","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0105","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.amjcard.2014.02.029","article-title":"Correlation between extent of myocardial fibrosis assessed by cardiac magnetic resonance and cardiac troponin T release in patients with nonischemic heart failure","volume":"113","author":"Takashio","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10741-011-9272-0","article-title":"Right side of heart failure","volume":"17","author":"Guglin","year":"2012","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1532-429X-14-11","article-title":"Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension","volume":"14","author":"Freed","year":"2012","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0120","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2010.06.062","article-title":"Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death","volume":"57","author":"Iles","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-065X.2009.00794.x","article-title":"The regulation of inflammation by galectin-3","volume":"230","author":"Henderson","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/HYPERTENSIONAHA.111.190512","article-title":"Aldosterone inhibits antifibrotic factors in mouse hypertensive heart","volume":"59","author":"Azibani","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2015.02.008_bb0135","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0140","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.jacc.2012.05.032","article-title":"Galectin-3 in cardiovascular disease: a possible window into early myocardial fibrosis","volume":"60","author":"Morrow","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.02.008_bb0145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223","article-title":"Cappola TP. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure","volume":"4","author":"Ky","year":"2011","journal-title":"Circ. Heart Fail."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315001254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315001254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:36:10Z","timestamp":1759091770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527315001254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":29,"alternative-id":["S0167527315001254"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.02.008","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}